Bionano Genomics shares surge 21.09% premarket on Q3 revenue growth, improved margins, and CPT code progress.

Bionano Genomics (NASDAQ:BNGO) surged 21.09% in premarket trading following the release of its Q3 2025 earnings report, which highlighted a 21% year-over-year revenue increase to $7.4 million, driven by 12% core revenue growth and seven new optical genome mapping (OGM) system installations. The company also reported a 46% non-GAAP gross margin, a 40% reduction in operating expenses, and a strategic milestone with the CMS establishing a Category I CPT code for OGM reimbursement. These results, coupled with a $10 million capital raise and updated revenue guidance, signaled improved financial discipline and long-term growth potential. The premarket rally reflects investor optimism over the company’s operational progress and reimbursement advancements, despite a 7.5% prior-day decline.